CAI logo

Caris Life Sciences Inc. (CAI)

$21

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CAI

Market cap

$6.02B

EPS

0.05

P/E ratio

--

Price to sales

8.48

Dividend yield

--

Beta

0.703756

Price on CAI

Previous close

$23.04

Today's open

$22.62

Day's range

$20.95 - $22.62

52 week range

$14.19 - $36.50

Profile about CAI

CEO

David Dean Halbert

Employees

1846

Headquarters

Irving, TX

Exchange

Nasdaq Global Select

Shares outstanding

286784504

Issue type

Common Stock

CAI industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CAI

BTSG vs. CAI: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical Services sector might want to consider either BrightSpring Health Services, Inc. (BTSG) or Caris Life Sciences,?Inc. (CAI). But which of these two companies is the best option for those looking for undervalued stocks?

news source

Zacks Investment Research • Nov 9, 2026

news preview

Caris Life Sciences Q3 Earnings Call Highlights

Caris Life Sciences NASDAQ: CAI raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company also reported lower quarterly profit as it increased spending on its sales force, marketing and new tests.

news source

MarketBeat • Nov 5, 2026

news preview

Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript

Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period.

news source

PRNewsWire • Nov 4, 2026

news preview

Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates

Caris Life Sciences,?Inc. (CAI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.08 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for

Caris Life Sciences,?Inc. (CAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection

New campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of the second commercial in a series promoting Caris Detect™, Caris' multi-cancer early detection (MCED) test, featuring three-time major champion professional golfer, Jordan Spieth. The campaign emphasizes that while modern technology can measure nearly every aspect of athletic performance, the same level of intelligence can be applied to helping people find early stage cancer – when treatment is most effective.

news source

PRNewsWire • Oct 19, 2026

news preview

Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November 4, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.

news source

PRNewsWire • Oct 15, 2026

news preview

Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026

Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer types IRVING, Texas, Oct. 14, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tumor types.

news source

PRNewsWire • Oct 14, 2026

news preview

IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months

Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.

news source

Investors Business Daily • Oct 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Caris Life Sciences Inc.

Open an M1 investment account to buy and sell Caris Life Sciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CAI on M1